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A novel 2009 influenza A (H1N1) virus, which began
its spread in Mexico, was raised to global prominence in
April 2009 due to its high mortality rate, and the World
Health Organization declared the first influenza pan-
demic in June 2009.1 The history of influenza pan-
demics include outbreaks recorded in 1918 (Spanish
flu), 1957 (Asian flu), and 1968 (Hong Kong flu). It
is estimated that the cycle of influenza pandemics
occurs every 30–50 years. An early finding suggested
that the mortality rate caused by the novel H1N1
influenza virus is less than that of the 1918 outbreak
but comparable to that of the 1957 outbreak.2
Although several antiviral agents, such as oseltamivir
(Tamiflu) and zanamavir (Relenza), are available, the
best way to prevent the disease is to have an effective
vaccine.3 Most recent studies have indicated that a
single 15-μg dose of 2009 H1N1 vaccine is immuno-
genic, defined as antibody titers of 1:40 or more by
hemagglutination-inhibition assay, in 89–95% of adults
and in 92–97% of infants and children, with mild-to-
moderate vaccine-associated reactions.4,5
Given the successful initial results of the vaccination
strategy against the H1N1 influenza virus, several
critical issues remain unexplored. The major concerns
of using a new vaccine against a specific infectious dis-
ease include the safety, immunogenicity and efficacy
of the vaccine. The health authority in Taiwan began
the H1N1 mass vaccination program in November
2009. However, information regarding important
vaccine-related issues has not been fully disclosed to
the public. Quite a few deaths have occurred after the
injection of the H1N1 vaccine. Although a direct
causal relationship between the vaccine and mortality
cannot be firmly established, the safety of the vaccine
has become a serious concern in Taiwan. In addition,
since the presentation of H1N1 influenza could be
subclinical, the prevalence rate of the infection and
baseline antibody titers against H1N1 influenza among
susceptible hosts are largely unknown. This informa-
tion is crucial because the efficacy of the protective
ability of the vaccine needs to be demonstrated, and
the vaccination may not be needed in already-infected
subjects. Moreover, certain risk groups, such as hospital
personnel, may have a higher risk of contracting H1N1
infection because of more frequent contact with
patients. Subjects who have acquired antibodies to the
H1N1 virus without vaccination are likely to be exposed
to unnecessary risks of vaccine-associated adverse events
if they are subsequently vaccinated.
The Taipei Veterans General Hospital (TVGH),
which has 2,900 beds for hospitalization and a capacity
of 8,000–10,000 outpatients daily, is the major teach-
ing hospital in Taiwan. Our hospital provides primary
to tertiary medical care to the residents of northern
Taiwan, an area of 11 million inhabitants. According
to a recent internal survey from the Infection Control
Unit of TVGH during the period between August
24, 2009 and January 11, 2010, 1,850 (20.7%) of
8,928 patients (including in- and outpatients) who
underwent a rapid point-of-care testing had influenza
A. Our data are consistent with those of another
study from Spain.6 During the same period of time,
35 hospital staff were confirmed to have influenza A; all
of them recovered uneventfully after supportive treat-
ment. This large number of infected subjects indicates
that hospital staff are invariably exposed to a highly
infectious environment. In this issue of the Journal of
the Chinese Medical Association, Chan et al7 analyzed
the seropositive rate of H1N1 virus in the medical
personnel of TVGH. Strikingly, the seropositive rate
of the H1N1 influenza virus was 20%, which was sig-
nificantly higher than that in the general population
(2.9%). Subgroup analysis showed that among the
medical personnel, the rate was higher in the medical
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staff and nurses from the Department of Infectious
Disease, Emergency Room and inpatient wards (30.8%)
than in laboratory and administrative staff (12.6%).
These data show that an amazingly high proportion of
hospital staff have previously been infected by the
H1N1 influenza virus, and imply that the hospital
itself is a potential incubator of the H1N1 virus.
These results also raise a concern that susceptible 
subjects, especially high-risk groups such as medical
personnel, need to undergo baseline antibody titer
measurement before vaccination.
Different countries have different vaccination
policies against H1N1 influenza infection. In the
United States, although no substantial differences
between H1N1 and seasonal influenza vaccines were
noted in the proportion or types of serious adverse
events reported,8 many people in Taiwan are still
reluctant to undergo a free flu shot. The hindrance to
the H1N1 vaccination program in Taiwan could be
attributed to the uncertainties and potentially serious
side effects of this new vaccine. Although the initial
mortality rate of the H1N1 influenza virus in Mexico
appeared alarmingly high, subsequent reports from
other countries did not show consistent results. More
and more evidence suggest that the novel H1N1
influenza could only be an average seasonal flu that
does not induce particularly high mortality rates. In
addition, whether the current vaccination policy will
generate undue benefit to the vaccine-producing
pharmaceutical companies is another issue of con-
cern. An emergency debate on this issue is ongoing
by the Council of Europe. Although we cannot infer
that the H1N1 outbreak in 2009 was a false alarm at
this point in time, the story of influenza pandemics will
repeat itself and thus more detailed epidemiological,
clinical and laboratory information should be gath-
ered and inspected during each outbreak before pub-
lic resources and money are spent on a massive scale.
The vaccination strategy needs to be re-evaluated in
the hopes of further minimizing unnecessary risks and
frequency of severe vaccine-associated adverse events.
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